AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PTHS

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

Original reporting
finance.yahoo.com
Published Nov 13, 2026, 12:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pelthos (PTHS) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PTHSBullishMed
01

Why it matters

The earnings beat and acquisition announcement provide fresh catalysts that could move the stock.

02

Market read

First‑time earnings disclosure and a strategic M&A deal make this a high‑impact biotech news item.

03

What to watch

Potential regulatory hurdles for the gene‑therapy asset and cash burn from scaling manufacturing.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Pelthos is a dermatology-focused biotech reporting its Q3 2026 results and a pending acquisition of Castle Creek Biosciences.

Company-level read

Ticker impact

$PTHSBullishHigh confidence
Context

Q3 2026 earnings call disclosed net revenue of $15.2M, 114% YoY growth and announced a Castle Creek acquisition.

Expected impact

likely upward pressure as investors price in higher growth and acquisition synergies

Evidence & confidence

First disclosure of earnings and a material M&A deal provides fresh, material information for traders.

Market effects

Sector

Highlights continued consolidation in dermatology biotech and could lift peer valuations.

Regional

US biotech sector may see modest gains; European peers less affected.

Global

Limited to biotech investors, no broad macro impact.

Counterpoint

What could challenge this read

Acquisition risk and integration challenges could weigh on the stock if execution falters.

Key entities

  • company
    Pelthos

    US‑listed biotech (ticker PTHS) reporting Q3 2026 results.

  • company
    Castle Creek Biosciences

    Target of Pelthos acquisition, developer of D‑Fi gene‑therapy.

Read at source← All news

Also covered by

1 outlet

Related articles

$PTHSMed

Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Pelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update Zelsuvmi ® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025 12,384 Zelsuvmi units were dispe

SEC EDGAR 8-K
$PTHSHighAI 8/10

Pelthos and Castle Creek plan merger to target skin diseases

Pelthos Therapeutics (PTHS) will merge with Castle Creek Biosciences, focusing on skin diseases. The deal, approved by both boards, is expected to close by Q1 2027. Castle Creek shareholders will receive 5.2 million Pelthos shares, with potential for more if D-Fi, a gene-modified cell therapy, gains FDA approval. The combined company will trade on the NYSE American under PTHS.

finance.yahoo.com
$PTHSHighAI 9/10

Pelthos Therapeutics to merge with Castle Creek Biosciences

Pelthos Therapeutics (NYSE: PTHS) will merge with Castle Creek Biosciences, a late-stage gene therapy company. Pelthos shares fell 43% to $9.40 on the news. The combined company will focus on skin diseases, using Castle Creek's fibroblast-based platform and Pelthos' FDA-approved products, and will trade as Pelthos Therapeutics (PTHS).

thepharmaletter.com